Nelarabine
Template:Short description Template:Use dmy dates Template:Drugbox
Nelarabine, sold under the brand names Arranon (US) and Atriance (EU), is a chemotherapy medication used for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).<ref name="Arranon FDA label" /><ref name="Atriance EPAR" />
Nelarabine is a prodrug of arabinosylguanine nucleotide triphosphate (araGTP), a type of purine nucleoside analog, which causes inhibition of DNA synthesis and cytotoxicity.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens.<ref name="Example2006a">Template:Cite journal</ref> It was later approved in the European Union in October 2005.<ref name="Atriance EPAR" /> It is available as a generic medication.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>
References
External links
- {{#invoke:citation/CS1|citation
|CitationClass=web }}
- {{#invoke:citation/CS1|citation
|CitationClass=web }}Template:Dead link
{{#invoke:Navbox|navbox}} Template:Portal bar